Roche said a late-stage clinical trial has shown the Swiss drugmaker’s influenza drug baloxavir marboxil significantly sped time to relief for patients highly vulnerable to serious complications.
Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.
Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.
Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.
The U.S. FDA accepted a New Drug Application and granted Priority Review for Genentech’s baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older.
Statement from FDA Commissioner Scott Gottlieb, M.D. on the efficacy of the 2017-2018 influenza vaccine
Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.
German biotech firm CureVac secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza.
A private British company is developing a vaccine that would be the first in the world to fight all types of flu.
Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
A seasonal flu vaccine that would be the world’s first to fight all types of the virus will be tested in a two-year study involving 2,000+ patients by Oxford researchers.
Provention Bio agreed to in-license two clinical-stage assets for immune-mediated diseases from Janssen Pharmaceutica and Janssen Sciences Ireland.
In meeting with industry analysts, J&J indicated it expects to have 10 new products approved between 2017 and 2021 that have blockbuster potential.
GlaxoSmithKline announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza Vaccine) for infants 6 months and older.
The U.S. Department of Agriculture has $80 million to $90 million left over from the last major outbreak of bird flu to fight any new discoveries of the virus, the department’s chief veterinary officer said.
The United States reported an outbreak of avian flu on a farm in Wisconsin, the second in the country in less than a week although the virus found this time is considered less virulent, the World Organisation for Animal Health (OIE) said.
Britain said it had detected bird flu on premises in eastern England during routine checks carried out following the confirmation of the virus at a nearby farm.
Four years ago, a bird flu outbreak in China killed at least three dozen people, triggered mass poultry culling, put masks on millions of Chinese faces and hammered shares in fast food and travel companies. During the winter of 2016/2017, more than 100 people have died, but few birds have been slaughtered, there are few masks on the streets and little sign of any consumer reaction, let alone the panic seen in 2013.
The first generic copy of Roche’s top-selling flu pill Tamiflu hit the U.S. market, marking a further step in the Swiss drugmaker’s enforced evolution to reliance on a new wave of blockbuster medicines.
Shares of Novavax plummeted more than 82 percent after the company released data that its Phase III trial for its RSV F Vaccine for older adults did not meet its goals, failing to demonstrate “vaccine efficacy.”